The Evolving Role of BTK Inhibitors in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

June 20th 2022

Medical experts detail the current and evolving roles of BTK inhibitors in treatment of patients with relapsed/refractory mantle cell lymphoma.

Future Directions in Treatment of Chronic Lymphocytic Leukemia (CLL) with BTK Inhibitors

February 24th 2022

Experts in hematology/oncology share key insight on the treatment of CLL, including the use of BTK inhibitors and the critical role of pharmacists in disease management.

The Evolving Treatment Landscape in CLL: Updates from ASH 2021

December 21st 2021

Considerations regarding updates to chronic lymphocytic leukemia treatment algorithms based on novel and emerging therapies presented at the ASH 2021 annual meeting.

Treatment Innovations in Waldenstrom Macroglobulinemia

December 17th 2021

Pharmacist and provider perspective on BTK inhibitors for Waldenstrom macroglobulinemia.

Treatment Innovations in Relapsed/Refractory Marginal Zone Lymphoma

November 22nd 2021

Shared insight on unmet needs and recent innovations in the management of marginal zone lymphoma in the relapsed/refractory setting.

On the Shelf Video Series

November 17th 2021

Joanna Lewis, PharmD, MBA, discusses practical considerations when selecting over-the-counter medications to treat common conditions pharmacists are often asked about and highlights some recommended medications from the Pharmacy Times’ OTC Guide

Second-line Maintenance Therapy in Ovarian Cancer: PARP Inhibitors

September 30th 2021

Bhavesh Shah, RPh, BCOP; and Thomasina Morris, RPh, MHA, BCOP, discuss the importance of utilizing PARP inhibitors as second-line maintenance therapy in ovarian cancer and share valuable clinical insights.

Targeted Therapy Treatment Innovations in AML

August 26th 2021

Optimizing Patient Outcomes with Prescription Discount Programs

July 12th 2021

Innovations in the Treatment of Chronic Lymphocytic Leukemia

June 30th 2021

A discussion on advancements and updates in the treatment of CLL, including the latest research presented at the 2021 American Society of Clinical Oncology Virtual Meeting.